ARTA
NMTR

A.R.T. Advisors’s 9 Meters Biopharma NMTR Stock Holding History

A.R.T. Advisors’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-715
Closed -$28K – 1711
2019
Q1 		$28K Buy
+715
New +$30.9K ﹤0.01% 1245
2018
Q4 		– Sell
-2,674
Closed -$365K – 1760
2018
Q3 		$365K Buy
+2,674
New +$459K 0.02% 970

Other funds holding NMTR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

A.R.T. Advisors's NMTR Position: Q2 2019 in Review

A.R.T. Advisors sold out of 9 Meters Biopharma (NMTR) in Q2 2019, closing a stake of 715 shares — an estimated $28K sold.

A.R.T. Advisors first reported a position in NMTR in Q3 2018 and held it in 2 quarters. The position peaked at $365K in Q3 2018. 30 funds tracked by Wall St. Rank hold NMTR as of Q2 2019.

  • A.R.T. Advisors reported no remaining 9 Meters Biopharma position as of Q2 2019 after selling out during the quarter.
  • A.R.T. Advisors sold 715 9 Meters Biopharma shares in Q2 2019, an estimated $28K.
  • A.R.T. Advisors first reported a position in 9 Meters Biopharma in Q3 2018 and held it in 2 quarters.
  • A.R.T. Advisors's 9 Meters Biopharma position peaked at $365K in Q3 2018.
  • 30 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2019.

Based on A.R.T. Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.